181 related articles for article (PubMed ID: 34282500)
1. Secondary Packages cannot Protect Liquid Biopharmaceutical Formulations from Dropping-Induced Degradation.
Fang WJ; Liu JW; Gao H; Qian YC; Gao JQ; Wang H
Pharm Res; 2021 Aug; 38(8):1397-1404. PubMed ID: 34282500
[TBL] [Abstract][Full Text] [Related]
2. Effects of Secondary Package on Freeze-Dried Biopharmaceutical Formulation Stability During Dropping.
Fang WJ; Liu JW; Barnard J; Wang H; Qian YC; Xu J
J Pharm Sci; 2021 Aug; 110(8):2916-2924. PubMed ID: 33940028
[TBL] [Abstract][Full Text] [Related]
3. Freeze-Dried Biopharmaceutical Formulations are Surprisingly Less Stable than Liquid Formulations during Dropping.
Fang WJ; Pang MJ; Liu JW; Wang X; Wang H; Sun MF
Pharm Res; 2022 Apr; 39(4):795-803. PubMed ID: 35314998
[TBL] [Abstract][Full Text] [Related]
4. Protein Sub-Visible Particle and Free Radical formation of a Freeze-Dried Monoclonal Antibody Formulation During Dropping.
Fang WJ; Liu JW; Zheng HJ; Shen BB; Wang X; Kong Y; Jing ZY; Gao JQ
J Pharm Sci; 2021 Apr; 110(4):1625-1634. PubMed ID: 33049261
[TBL] [Abstract][Full Text] [Related]
5. Freeze-Dried Monoclonal Antibody Formulations are Unexpectedly More Prone to Degradation Than Liquid Formulations Under Shaking Stress.
Fang WJ; Ingle RG; Liu JW; Ge XZ; Wang H
J Pharm Sci; 2022 Jul; 111(7):2134-2138. PubMed ID: 35257695
[TBL] [Abstract][Full Text] [Related]
6. The Effects of Excipients on Freeze-dried Monoclonal Antibody Formulation Degradation and Sub-Visible Particle Formation during Shaking.
Jin MJ; Ge XZ; Huang Q; Liu JW; Ingle RG; Gao D; Fang WJ
Pharm Res; 2024 Feb; 41(2):321-334. PubMed ID: 38291165
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Grinding-Induced Subvisible Particles and Free Radicals in a Freeze-Dried Monoclonal Antibody Formulation.
Jing ZY; Huo GL; Sun MF; Shen BB; Fang WJ
Pharm Res; 2022 Feb; 39(2):399-410. PubMed ID: 35083639
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability.
Tomlinson A; Zarraga IE; Demeule B
Mol Pharm; 2020 Jul; 17(7):2345-2353. PubMed ID: 32442382
[TBL] [Abstract][Full Text] [Related]
9. Evaluation and Screening of Biopharmaceuticals using Multi-Angle Dynamic Light Scattering.
Sharma A; Beirne J; Khamar D; Maguire C; Hayden A; Hughes H
AAPS PharmSciTech; 2023 Mar; 24(4):84. PubMed ID: 36949219
[TBL] [Abstract][Full Text] [Related]
10. Detection and Sizing of Submicron Particles in Biologics With Interferometric Scattering Microscopy.
Wong NA; Uchida NV; Dissanayake TU; Patel M; Iqbal M; Woehl TJ
J Pharm Sci; 2020 Jan; 109(1):881-890. PubMed ID: 31160046
[TBL] [Abstract][Full Text] [Related]
11. Analytical Platform for Monitoring Aggregation of Monoclonal Antibody Therapeutics.
Bansal R; Gupta S; Rathore AS
Pharm Res; 2019 Aug; 36(11):152. PubMed ID: 31463609
[TBL] [Abstract][Full Text] [Related]
12. Investigation of excipients impact on polysorbate 80 degradation in biopharmaceutical formulation buffers.
Bai L; Zhang Y; Zhang C; Lu Y; Li Z; Huang G; Meng B
J Pharm Biomed Anal; 2023 Sep; 233():115496. PubMed ID: 37285658
[TBL] [Abstract][Full Text] [Related]
13. Formation of protein sub-visible particles during powder grinding of a monoclonal antibody.
Qian C; Wang G; Wang X; Barnard J; Gao JQ; Bao W; Wang H; Li F; Ingle RG; Fang WJ
Eur J Pharm Biopharm; 2020 Apr; 149():1-11. PubMed ID: 32006605
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a selective marker-based quantification of polysorbate 20 in biopharmaceutical formulations using UPLC QDa detection.
Evers DH; Schultz-Fademrecht T; Garidel P; Buske J
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1157():122287. PubMed ID: 33069954
[TBL] [Abstract][Full Text] [Related]
15. Physicochemical Stability of Monoclonal Antibodies: A Review.
Le Basle Y; Chennell P; Tokhadze N; Astier A; Sautou V
J Pharm Sci; 2020 Jan; 109(1):169-190. PubMed ID: 31465737
[TBL] [Abstract][Full Text] [Related]
16. Controlled polysorbate 20 hydrolysis - A new approach to assess the impact of polysorbate 20 degradation on biopharmaceutical product quality in shortened time.
Graf T; Abstiens K; Wedekind F; Elger C; Haindl M; Wurth C; Leiss M
Eur J Pharm Biopharm; 2020 Jul; 152():318-326. PubMed ID: 32445968
[TBL] [Abstract][Full Text] [Related]
17. Mixing monoclonal antibody formulations using bottom-mounted mixers: impact of mechanism and design on drug product quality.
Gikanga B; Chen Y; Stauch OB; Maa YF
PDA J Pharm Sci Technol; 2015; 69(2):284-96. PubMed ID: 25868994
[TBL] [Abstract][Full Text] [Related]
18. Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism.
Tomlinson A; Demeule B; Lin B; Yadav S
Mol Pharm; 2015 Nov; 12(11):3805-15. PubMed ID: 26419339
[TBL] [Abstract][Full Text] [Related]
19. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
[TBL] [Abstract][Full Text] [Related]
20. Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation.
Doshi N; Martin J; Tomlinson A
Mol Pharm; 2020 Nov; 17(11):4354-4363. PubMed ID: 32941040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
